(Q36844513)

English

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

scientific article published on April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study (English)

1 reference

Europe PubMed Central

16 August 2017

1 reference

based on heuristic

inferred from title

lupus erythematosus

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Michelle A. Petri

1

object named as

Michelle Petri

1 reference

Europe PubMed Central

16 August 2017

Kenneth C. Kalunian

5

object named as

Kenneth Kalunian

1 reference

Europe PubMed Central

16 August 2017

author name string

Daniel J Wallace

2

1 reference

Europe PubMed Central

16 August 2017

Alberto Spindler

3

1 reference

Europe PubMed Central

16 August 2017

Vishala Chindalore

4

1 reference

Europe PubMed Central

16 August 2017

Eduardo Mysler

6

1 reference

Europe PubMed Central

16 August 2017

C Michael Neuwelt

7

1 reference

Europe PubMed Central

16 August 2017

Gabriel Robbie

8

1 reference

Europe PubMed Central

16 August 2017

Wendy I White

9

1 reference

Europe PubMed Central

16 August 2017

Brandon W Higgs

10

1 reference

Europe PubMed Central

16 August 2017

Yihong Yao

11

1 reference

Europe PubMed Central

16 August 2017

Liangwei Wang

12

1 reference

Europe PubMed Central

16 August 2017

Dominique Ethgen

13

1 reference

Europe PubMed Central

16 August 2017

Warren Greth

14

1 reference

Europe PubMed Central

16 August 2017

publication date

1 April 2013

1 reference

Europe PubMed Central

16 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

16 August 2017

65

1 reference

Europe PubMed Central

16 August 2017

1011-1021

1 reference

Europe PubMed Central

16 August 2017

4

1 reference

Europe PubMed Central

16 August 2017

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The type I interferon system in the development of lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The interferon-alpha signature of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Anticytokine therapies in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The socioeconomic burden of SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

New directions in the treatment of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Why can't we find a new treatment for SLE?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The genetic contribution to systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Health-related quality of life in patients with systemic lupus erythematosus: an update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Lessons learned from clinical trials in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Type I interferon correlates with serological and clinical manifestations of SLE

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

29 September 2017

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

27 June 2018

Systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

5 September 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

5 September 2018

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3654174

5 September 2018

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

https://api.crossref.org/works/10.1002%2FART.37824

21 January 2018

Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.37824

21 January 2018

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23400715

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.37824

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36844513&oldid=1660305022"